Genmab A/S (NASDAQ:GMAB) Announces Earnings Results

Genmab A/S (NASDAQ:GMAB) announced its earnings results on Wednesday. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03), Zacks reports. The business had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. During the same quarter in the previous year, the company earned $0.47 EPS. Genmab A/S updated its FY 2024 guidance to EPS.

Genmab A/S Price Performance

Genmab A/S stock opened at $23.11 on Friday. The business has a 50 day simple moving average of $24.57 and a 200 day simple moving average of $26.47. The company has a market capitalization of $15.29 billion, a PE ratio of 19.10, a price-to-earnings-growth ratio of 0.68 and a beta of 0.99. Genmab A/S has a one year low of $21.90 and a one year high of $32.89.

Analyst Upgrades and Downgrades

GMAB has been the topic of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research note on Wednesday, October 16th. Morgan Stanley reiterated an “equal weight” rating and issued a $31.00 target price on shares of Genmab A/S in a research note on Wednesday, September 11th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. Truist Financial cut their price target on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a report on Monday, September 9th. Finally, Royal Bank of Canada upgraded Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.